Skip to content
OpenCapital
Get started

CorMedix CRMD Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$488.08M+23.4%
ITG
Integer HoldingsITGR
$8.12M-74.4%
IAR
Integra LifeSciencesIART
$236.81M-1.0%
MiMedx Group logo
MiMedx GroupMDXG
$159.77M+50.1%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×—
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%—
Net margin45.2%—
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%—
Debt / equity0×0.0×
Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's cash & equivalents?
CorMedix (CRMD) reported cash & equivalents of $179.08M in Q1 2026.
How has CorMedix's cash & equivalents changed year-over-year?
CorMedix's cash & equivalents increased by 169.7% year-over-year, from $66.39M to $179.08M.
What is the long-term trend for CorMedix's cash & equivalents?
Over 5 years (2020 to 2025), CorMedix's cash & equivalents has grown at a 28.2% compound annual growth rate (CAGR), from $42.1M to $145.83M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.